BUZZ-Arcellx rises as Guggenheim lifts PT, reiterates 'buy' rating

Reuters

Oct 17, 2024

** Shares of Arcellx up about 2.5% at $92 in afternoon trading

** Brokerage Guggenheim raises ACLX's PT to $105 from $77, maintains "buy" rating

** Brokerage continues to see an opportunity for co's lead product, anito-cel, to be the best therapy of its kind to treat a type of blood cancer called multiple myeloma

** Anito-cel is a CAR-T therapy, which uses modified T-cells of patients to fight cancer, and is being tested for multiple myeloma that relapses or stops responding to the treatment

** ACLX plans to present initial data from a mid-stage trial for anito-cel in December

** Brokerage says investors are expecting the initial data to show better efficacy for anito-cel compared to Johnson & Johnson - Legend Biotech's Carvykti

** Stock up ~66% YTD, including session's gains

(Reporting by Sruthi Narasimha Chari in Bengaluru)

((Sruthinarasimha.chari@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2476949057"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2476949057\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2476949057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-17 00:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476949057","market":"us","top_or_hot":-1,"title":"BUZZ-Arcellx rises as Guggenheim lifts PT, reiterates 'buy' rating","media":"Reuters","content":"<html><body><p>** Shares of Arcellx    up about 2.5% at $92 in afternoon trading</p><p>   ** Brokerage Guggenheim raises ACLX's PT to $105 from $77, maintains \"buy\" rating</p><p>   ** Brokerage continues to see an opportunity for co's lead product, anito-cel, to be the best therapy of its kind to treat a type of blood cancer called multiple myeloma</p><p>       ** Anito-cel is a CAR-T therapy, which uses modified T-cells of patients to fight cancer, and is being tested for multiple myeloma that relapses or stops responding to the treatment</p><p>   ** ACLX plans to present initial data from a mid-stage trial for anito-cel in December</p><p>   ** Brokerage says investors are expecting the initial data to show better efficacy for anito-cel compared to Johnson &amp; Johnson - Legend Biotech's Carvykti</p><p>   ** Stock up ~66% YTD, including session's gains</p><p> (Reporting by Sruthi Narasimha Chari in Bengaluru)</p><p>((Sruthinarasimha.chari@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Arcellx rises as Guggenheim lifts PT, reiterates 'buy' rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Arcellx rises as Guggenheim lifts PT, reiterates 'buy' rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-17 00:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>** Shares of Arcellx    up about 2.5% at $92 in afternoon trading</p><p>   ** Brokerage Guggenheim raises ACLX's PT to $105 from $77, maintains \"buy\" rating</p><p>   ** Brokerage continues to see an opportunity for co's lead product, anito-cel, to be the best therapy of its kind to treat a type of blood cancer called multiple myeloma</p><p>       ** Anito-cel is a CAR-T therapy, which uses modified T-cells of patients to fight cancer, and is being tested for multiple myeloma that relapses or stops responding to the treatment</p><p>   ** ACLX plans to present initial data from a mid-stage trial for anito-cel in December</p><p>   ** Brokerage says investors are expecting the initial data to show better efficacy for anito-cel compared to Johnson &amp; Johnson - Legend Biotech's Carvykti</p><p>   ** Stock up ~66% YTD, including session's gains</p><p> (Reporting by Sruthi Narasimha Chari in Bengaluru)</p><p>((Sruthinarasimha.chari@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2476949057","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476949057","pubTimestamp":1729097001,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of Arcellx    up about 2.5% at $92 in afternoon trading   ** Brokerage Guggenheim raises ACLX's PT to $105 from $77, maintains \"buy\" rating   ** Brokerage continues to see an opportunity for","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生","ACLX":"ARCELLX, INC.","LEGN":"传奇生物"},"translate_title":"BUZZ-Arcellx上涨，古根海姆提高PT，重申“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":0.9,"JNJ":0.9,"PT":1,"ACLX":0.9},"content_text":"** Shares of Arcellx    up about 2.5% at $92 in afternoon trading   ** Brokerage Guggenheim raises ACLX's PT to $105 from $77, maintains \"buy\" rating   ** Brokerage continues to see an opportunity for co's lead product, anito-cel, to be the best therapy of its kind to treat a type of blood cancer called multiple myeloma       ** Anito-cel is a CAR-T therapy, which uses modified T-cells of patients to fight cancer, and is being tested for multiple myeloma that relapses or stops responding to the treatment   ** ACLX plans to present initial data from a mid-stage trial for anito-cel in December   ** Brokerage says investors are expecting the initial data to show better efficacy for anito-cel compared to Johnson & Johnson - Legend Biotech's Carvykti   ** Stock up ~66% YTD, including session's gains (Reporting by Sruthi Narasimha Chari in Bengaluru)((Sruthinarasimha.chari@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}